Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Convalescent plasma transfusion a promising therapy for coronavirus diseases 2019 (COVID-19): current updates

Convalescent plasma transfusion a promising therapy for coronavirus diseases 2019 (COVID-19):... While there is no proven treatment available for coronavirus disease 2019 (COVID-19), convalescent plasma (CP) may provide therapeutic relief as the number of cases escalate steeply world-wide. At the time of writing this review, vaccines, monoclonal antibodies or drugs are still lacking for the recent large COVID-19 outbreak, which restores the interest in CP as an empirical life-saving treatment. However, formal proof of efficacy is needed. The purpose of this review is to summarize all historical clinical trials on COVID-19 infected patients treated with CP to provide precise evidence for the efficacy and effectiveness of CP therapy in severe COVID-19 patients. Although there are many clinical trials in progress, high-quality clinical evidence is still lacking to analyze the existing problems. Meanwhile, based on the previous successful outcomes, we recommend healthcare systems to use CP therapy cautiously in critically ill COVID-19 patients. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Antibody Therapeutics Oxford University Press

Convalescent plasma transfusion a promising therapy for coronavirus diseases 2019 (COVID-19): current updates

Download PDF
11 pages

Loading next page...
 
/lp/oxford-university-press/convalescent-plasma-transfusion-a-promising-therapy-for-coronavirus-xwHaXs2e0Q
Publisher
Oxford University Press
Copyright
The Author(s) 2020. Published by Oxford University Press on behalf of Antibody Therapeutics. All rights reserved. For Permissions, please email: journals.permissions@oup.com
eISSN
2516-4236
DOI
10.1093/abt/tbaa010
Publisher site
See Article on Publisher Site

Abstract

While there is no proven treatment available for coronavirus disease 2019 (COVID-19), convalescent plasma (CP) may provide therapeutic relief as the number of cases escalate steeply world-wide. At the time of writing this review, vaccines, monoclonal antibodies or drugs are still lacking for the recent large COVID-19 outbreak, which restores the interest in CP as an empirical life-saving treatment. However, formal proof of efficacy is needed. The purpose of this review is to summarize all historical clinical trials on COVID-19 infected patients treated with CP to provide precise evidence for the efficacy and effectiveness of CP therapy in severe COVID-19 patients. Although there are many clinical trials in progress, high-quality clinical evidence is still lacking to analyze the existing problems. Meanwhile, based on the previous successful outcomes, we recommend healthcare systems to use CP therapy cautiously in critically ill COVID-19 patients.

Journal

Antibody Therapeutics – Oxford University Press

Published: May 27, 2020

Keywords: corona virus; COVID-19; pathogen inactivation; convalescent plasma; serology; Clinical trials

References

  • Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19
    Yang, Y; Shen, C; Li, J
  • Coronavirus-nephropathy; renal involvement in COVID-19
    Valizadeh, R; Baradaran, A; Mirzazadeh, A
  • Perspectives on the relationship of renal disease and coronavirus disease 2019
    Yalameha, B; Roshan, B; Bhaskar, LVKS
  • Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study
    Qiu, H; Wu, J; Hong, L
  • The third plague pandemic in Europe
    Bramanti, B; Dean, KR; Walloe, L
  • 1918 influenza: the mother of all pandemics
    Taubenberger, JK; Morens, DM
  • Pandemics, pathogenicity and changing molecular epidemiology of cholera in the era of global warming
    Chowdhury, FR; Nur, Z; Hassan, N
  • Pandemic influenza A (H1N1) virus infection and avian influenza A (H5N1) virus infection: a comparative analysis
    Korteweg, C; Gu, J
  • Molecular epidemiology, evolution and phylogeny of SARS coronavirus
    Luk, HKH; Li, X; Fung, J
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges
    Lai, CC; Shih, TP; Ko, WC
  • A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19
    Cao, B; Wang, Y; Wen, D
  • Convalescent plasma: new evidence for an old therapeutic tool?
    Marano, G; Vaglio, S; Pupella, S
  • Effectiveness of convalescent plasma therapy in severe COVID-19 patients
    Duan, K; Liu, B; Li, C
  • Experimental epidemic poliomyelitis in monkeys
    Flexner, S; Lewis, PA
  • A report on the serum treatment of twenty-six cases of epidemic poliomyelitis
    Amoss, HL; Chesney, AM
  • The use of convalescent human serum in influenza pneumonia-a preliminary report
    McGuire, LW; Redden, WR
  • Convalescent serum in prophylaxis of measles, chicken-pox, and mumps
    Gunn, W
  • Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection
    Hung, IF; To, KK; Lee, CK
  • The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis
    Mair-Jenkins, J; Saavedra-Campos, M; Baillie, JK
  • Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia
    Gutfraind, A; Meyers, LA
  • Covid-19: FDA approves use of convalescent plasma to treat critically ill patients
    Tanne, JH
  • The convalescent sera option for containing COVID-19
    Casadevall, A; Pirofski, LA
  • Convalescent plasma as a potential therapy for COVID-19
    Chen, L; Xiong, J; Bao, L
  • Treatment of 5 critically ill patients with COVID-19 with convalescent plasma
    Shen, C; Wang, Z; Zhao, F
  • Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients
    Chen, X; Zhao, B; Qu, Y
  • The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study
    Duan, K; Liu, B; Li, C
  • Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19
    Zhang, L; Pang, R; Xue, X
  • Treatment with convalescent plasma for COVID-19 patients in Wuhan, China [published online ahead of print, 2020 Apr 15]
    Ye, M; Fu, D; Ren, Y
  • Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019
    Zhao, J; Yuan, Q; Wang, H
  • A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between gender
    Zeng, F; Dai, C; Cai, P
  • Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63
    Chan, KH; Cheng, VC; Woo, PC
  • Hepatitis E virus in blood components: a prevalence and transmission study in Southeast England
    Hewitt, PE; Ijaz, S; Brailsford, SR
  • Noninfectious serious hazards of transfusion
    Hendrickson, JE; Hillyer, CD
  • The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy
    Triulzi, DJ; Kleinman, S; Kakaiya, RM
  • Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19
    Thevarajan, I; Nguyen, THO; Koutsakos, M
  • Antibody-dependent enhancement of severe dengue disease in humans
    Katzelnick, LC; Gresh, L; Halloran, ME
  • Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement
    Fleming, AB; Raabe, V
  • Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients
    Zeng, Q-L; Yu, Z-J; Gou, J-J